MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • MDS Virtual Congress 2020

    Improving automaticity of walking in Parkinson’s disease: Levodopa or Donepezil?

    S. Stuart, R. Morris, A. Giritharan, J. Quinn, J. Nutt, M. Mancini (Newcastle upon Tyne, United Kingdom)

    Objective: Determine whether levodopa replacement or cholinergic augmentation improve automaticity of walking in people with Parkinson’s disease (PD). Background: Degradation of dopaminergic striatal mechanisms of…
  • MDS Virtual Congress 2020

    Using a Delphi process to inform the design of disease modifying trials in Parkinson’s disease

    M. Zeissler, R. Windle, K. McFarthing, K. Raphael, G. Rafaloff, C. Carroll (Plymouth, United Kingdom)

    Objective: To consolidate current opinion on trial methodology of disease modifying therapies (DMTs) for Parkinson’s disease (PD) and establish consensus on a core protocol for…
  • MDS Virtual Congress 2020

    Levodopa and dopamine agonists dosage changes after Opicapone introduction

    N. Caballol, A. Planas-Ballvé, A. Ávila (Sant Joan Despí, Spain)

    Objective: We aim to analyze changes in levodopa and dopamine agonists (DA) dosage after introduction of opicapone (OPC) in a daily clinical practice setting. Background:…
  • MDS Virtual Congress 2020

    Maintenance of safinamide 100 mg daily long-term

    N. FONCEA (Galdakao, Spain)

    Objective: Evaluating the maintenance of safinamide 100 mg daily as a long-term treatment Background: The effects of safinamide were investigated in studies 016, 018 and…
  • MDS Virtual Congress 2020

    Frequency and risk factors of dopamine agonist-induced peripheral edema in patients with Parkinson’s disease

    S. Bostan, N. Durmaz Çelik, S. Özkan (Eskisehir, Turkey)

    Objective: To determine the frequency and risk factors of peripheral edema (PE) development and whether discontinuation of the drug is enough for treatment. To determine…
  • MDS Virtual Congress 2020

    Vitamin D assessment in patents with Parkinson’s disease

    N.A Mansurova, Y.N Madjidova (Tashkent, Uzbekistan)

    Objective: Analysis of the effectiveness of vitamin D in patients with PD depending on clinical manifestations and concentration levels of 25 (OH) D. Background: Recent…
  • MDS Virtual Congress 2020

    Management of parkinsonian patients with long-term DBS and incomplete control of symptoms

    I. Reuter (Giessen, Germany)

    Objective: We want to evaluate if apomorphine infusions can improve symptom control in PD patients with long standing DBS and functional decline. Background: Deep brain stimulation…
  • MDS Virtual Congress 2020

    Efficacy and safety of istradefylline in Parkinson’s disease patients with postural abnormality: Results from a multicenter, open-label study in Japan

    M. Takahashi, T. Shimokawa, J. Koh, T. Takeshima, H. Yamashita, Y. Kajimoto, A. Mori, H. Ito (Osaka, Japan)

    Objective: To investigate the efficacy and safety of istradefylline for the treatment of postural abnormality in patients with Parkinson’s disease (PD). Background: Postural abnormality in…
  • MDS Virtual Congress 2020

    Body Weight-Supported Treadmill Training Improves Walking Function in Multiple System Atrophy: A Case Report

    R. Hand, C. Testa (Richmond, VA, USA)

    Objective: Multiple system atrophy (MSA) is a rapidly progressive synucleinopathy involving autonomic dysfunction and impaired mobility. MSA has been further sub-classified into two phenotypes: parkinsonian…
  • MDS Virtual Congress 2020

    Characterising Oromandibular Dystonia in Multiple System Atrophy: A video analysis

    Y. Thongchuam, P. Panyakaew, R. Bhidayasiri (Bangkok, Thailand)

    Objective: To characterise craniofacial manifestations in patients with MSA and explore the relationship between OMD and other related symptoms and treatment. Background: According to the…
  • « Previous Page
  • 1
  • …
  • 122
  • 123
  • 124
  • 125
  • 126
  • …
  • 149
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley